February 1, 1986Circulation
Role of platelets and platelet inhibitors in aortocoronary artery vein-graft disease.
Key result
Dipyridamole plus aspirin reduced the rate of aortocoronary-artery bypass graft occlusion at 1 month and 1 year compared with placebo in 407 patients.
Why the study?
Does dipyridamole plus aspirin reduce the rate of graft occlusion in patients undergoing aortocoronary-artery bypass grafting?
Population
407 patients undergoing aortocoronary-artery bypass grafting
Comparison
Long-term administration of dipyridamole plus… vs Placebo
Design
RCT, Randomized, Double-blind
Follow-up
1 year
Authors
Discussion
Loading...
Member takes
Implication
Supports perioperative dipyridamole-aspirin in CABG to prevent graft occlusion; confirms randomized benefit over placebo.
Study Design
Type
RCT (n=407)
Blinding
Double-blind
Randomization
randomized
Structured PICO
Does dipyridamole plus aspirin reduce the rate of graft occlusion in patients undergoing aortocoronary-artery bypass grafting?
P
Population
407 patients undergoing aortocoronary-artery bypass grafting
I
Intervention
Long-term administration of dipyridamole (begun 2 days before operation) plus aspirin (begun 7 hours after operation)
C
Comparator
Placebo
O
Outcome
Rate of graft occlusion at 1 month and 1 yearsurrogate
Perioperative initiation of dipyridamole and aspirin reduces early and late thrombotic graft occlusion in patients undergoing aortocoronary bypass grafting.
Cite This Study
Fuster et al. (1986) conducted an RCT in aortocoronary artery vein-graft disease (n=407). dipyridamole plus aspirin vs. placebo was evaluated on graft occlusion. Dipyridamole plus aspirin reduced the rate of aortocoronary-artery bypass graft occlusion at 1 month and 1 year compared with placebo in 407 patients.